Journal of Psychoactive Drugs
November 10, 2025
Nicky J. Mehtani, Maha N. Mian, Gabrielle Agin-Liebes et al.
1 citation
Amid an evolving psychedelic drug policy landscape and limitations of existing substance use disorder (SUD) treatments, a novel addiction recovery paradigm has emerged involving augmentation of 12-Step program engagement with therapeutic psychedelic use. A preliminary qualitative analysis was initiated to describe this movement by examining real-world experiences of participants in remission...
BMJ Open
August 1, 2025
Nicky J. Mehtani, B. Anderson, Irina Alexander et al.
INTRODUCTION: Methamphetamine use disorder (MeUD) is a debilitating condition with no FDA-approved pharmacotherapies that has been associated with poor neurological, psychiatric and cardiovascular outcomes, particularly among low-income populations. The use of methamphetamine also increases risks for sexually transmitted infections (STIs) by reducing behavioural inhibitions while enhancing...
Nature Mental Health
May 1, 2025
Daniel H. Grossman, Kevin R. Madden, Nicky J. Mehtani et al.
10 citations
Socioeconomic status (SES) substantially influences mental health outcomes and treatment access, yet its reporting in psychedelic-assisted therapy trials remains underexplored. Here we systematically reviewed 98 articles (49 primary trials and 49 secondary analyses) published between 2006 and 2024 examining classic psychedelics and MDMA for mental health conditions. Only 12% of primary trials...
Psychiatric Research and Clinical Practice
February 11, 2025
Jules Evans, Marc Aixalà, Brian T Anderson et al.
18 citations
Objective: This article outlines recommendations from 30 psychedelic researchers on how to create a better psychedelic safety net. Methods: A survey of 30 psychedelic researchers asked them to identify key critical research gaps around psychedelic harm and safety. Results: The critical research gaps identified by the authors included defining the main types of psychedelic harm, the predictors...
Scientific Reports
August 2, 2024
Jennifer Mitchell, Nicky J. Mehtani, Mallory O. Johnson et al.
9 citations
Abstract As a proposed mediator between stigma-related stressors and negative mental health outcomes, HIV-related shame has been predictive of increased rates of substance use and difficulties adhering to antiretroviral treatment among people with HIV. These downstream manifestations have ultimately impeded progress toward national goals to End the HIV Epidemic , in part due to limited success...
Journal of Psychoactive Drugs
2024
Kelan Thomas, Robert L. Jesse, Nicky J. Mehtani et al.
4 citations
In recent years, policymakers have proposed and implemented regulatory changes promoting the deprioritization, decriminalization, or state-level legalization of one or more psychedelic substances, usually referencing data from clinical trials as reasons to support liberalizing drug control policies. As psychedelic policies continue to be drafted, personal possession limits may be considered for...